Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- Social Justice Institute’s Rhonda Y. Williams speaks at Movement for Black Lives Conference
- Weatherhead School’s J.B. Silvers discusses trend of health insurance company consolidation
- Leading AIDS researcher appointed to Fasenmyer Professorship in School of Medicine
- International students: Enroll in six-week Spoken English/Culture Seminar
- Last chance to attend a CWRU summer BBQ on the Quad